
Exact Sciences (EXAS) Stock Forecast & Price Target
Exact Sciences (EXAS) Analyst Ratings
Bulls say
Exact Sciences has raised its screening revenue guidance to $2.510-2.520 billion, reflecting an increase of $60 million at the midpoint, indicative of robust growth potential in its cancer screening market. The company's precision oncology revenue guidance has also been uplifted to $710-715 million, demonstrating a continued expansion of its genomic testing solutions. Additionally, the positive outlook is reinforced by an increase in adjusted EBITDA guidance to $470-480 million and expectations for continued market adoption of Cologuard, which is aimed at achieving over 40% market penetration in the long term.
Bears say
The financial performance of Exact Sciences has been challenged by its reliance on promotional marketing to drive demand for its Cologuard product, indicating sensitivity to fluctuations in marketing spending. Additionally, the company's history of net losses raises concerns about its ability to achieve and sustain GAAP profitability, with a projected growth impact of approximately 300-400 basis points in the fourth quarter. Compounding these issues, Exact's revenue estimates for 2027 remain below target, reflecting uncertainties related to competition and potential market dynamics.
This aggregate rating is based on analysts' research of Exact Sciences and is not a guaranteed prediction by Public.com or investment advice.
Exact Sciences (EXAS) Analyst Forecast & Price Prediction
Start investing in Exact Sciences (EXAS)
Order type
Buy in
Order amount
Est. shares
0 shares